Treatment of glaucoma using endothelin receptor antagonists
AssigneePerfuse Therapeutics, Inc.
InventorsSevgi Gurkan, David Floyd
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.
Claims24
1-24. (canceled)
A method of improving a visual function in a subject diagnosed with glaucoma, wherein the method comprises administering a therapeutically effective amount of edonentan, or a pharmaceutically acceptable salt thereof, in an optical tissue of said subject.
A method of improving a visual function in a subject diagnosed with glaucoma, wherein the method comprises administering about 50 μg to about 4 mg of edonentan, or a pharmaceutically acceptable salt thereof, in an optical tissue of said subject.
A method of improving optic nerve head blood flow in a subject diagnosed with glaucoma, wherein the method comprises administering a therapeutically effective amount of edonentan, or a pharmaceutically acceptable salt thereof, in an optical tissue of said subject.
Dependencies are inferred from the claim text.